Abstract Background Matrix metallopeptidase 9 (MMP9) has been implicated in a variety of
neurological disorders, including Alzheimer's disease (AD), where MMP9 levels are …

Lipoprotein receptor transport across the blood-brain barrier (BBB) mediates beta-amyloid
(Aβ) accumulation in the brain and may be a contributing factor in Alzheimer's disease (AD) …

J. Neurochem.(2012) 121, 239–251. Abstract Evidence accumulating during the past few
years points to a significant role of matrix metalloproteinase 9 (MMP9) enzymatic activity in …

Accumulation of amyloid-β (Αβ) peptide is believed to play a central role in the pathogenesis
of Alzheimer's disease (AD). Lowering Aβ levels in the brain may thus improve synaptic and …

We previously reported that deficiency of membrane-type five matrix metalloproteinase (MT5-
MMP) prevents amyloid pathology in the cortex and hippocampus of 5xFAD mice, and …

In Alzheimer's disease (AD), the expression of matrix metalloproteases (MMPs), which are
capable of degrading extracellular matrix proteins, is increased in the brain. Previous …

Abstract Matrix metalloproteinase‐9 (MMP‐9) is a member of the metzincin family of mostly
extracellularly operating proteases. Despite the fact that all of these enzymes might be target …

Abstract MMP13 (matrix metallopeptidase 13) plays a key role in bone metabolism and
cancer development, but has no known functions in Alzheimer's disease. In this study, we …

Background Membrane-type matrix metalloproteinase 5 (MT5-MMP) deficiency in the 5xFAD
mouse model of Alzheimer's disease (AD) reduces brain neuroinflammation and …

A hallmark of Alzheimer's disease (AD) is the accumulation of oligomeric amyloid-β (Aβ)
peptide, which may be primarily responsible for neuronal dysfunction. Insulin signaling …